Merck Clears Clinical Trial Milestone, Shows Promise With Alzheimer’s Drug Verubecestat A new drug developed by Merck shows promise for the treatment of Alzheimer’s disease. Verubecestat, which is currently under clinical trial, is said to halt the beta amyloid plaque formation in brain. by Saranya Palanisamy